DailySpaceUCrest Berhad
0005 · ACE Market创业板（ACE Market） · annual reports 2023 to 2025, 251 entries read2023 至 2025 年报，共读出 251 条
The company这家公司
UCrest is a mobile healthcare services provider whose flagship product is iMedic, a digital hospital platform that contributes the bulk of revenue alongside customization and maintenance services.UCrest 是一家移动医疗服务提供商，其旗舰产品为 iMedic 数字医院平台，贡献了大部分营业额，其余来自平台的定制与维护服务。
Sources (3)出处（3）
UCrest Technology Ltd. British Virgin Islands 100 100 Mobile healthcare services provider
The flagship product, iMedic™ contributed almost all the revenue and the remaining is attributed by customisation and maintenance services of the platform.
The flagship product, iMedic™, remained the primary revenue driver, contributing the bulk of income, while the balance came from customization and maintenance services related to the platform.
In 2025, international operations generated almost all revenue, with Singapore bringing RM18,060,194 and Malaysia bringing RM57,567; a single customer accounted for RM13,848,751 or 76% of total revenue.2025 年，国际业务几乎贡献了全部营业额，其中新加坡贡献 RM18,060,194，马来西亚贡献 RM57,567；单一客户占 RM13,848,751，即总营业额的 76%。
Sources (3)出处（3）
Singapore 18,060,194 15,295,951 - -
Malaysia 57,567 130,555 1,282,386 2,540,206
As at 31 May 2025, the Group recorded revenue and trade receivable of RM13,848,751 and RM31,461,675 respectively, representing 76% and 99% of the Group’s total revenue and total trade receivables respectively, which was derived from a customer.
Managing Director Eg Kah Yee holds 89,271,427 shares (12.001% in 2025) and also serves as Chairman; his brother Eg Kaa Chee sits on the board as a non-independent non-executive director.董事总经理 Eg Kah Yee 持有 89,271,427 股（2025 年占 12.001%）并兼任主席；其兄弟 Eg Kaa Chee 以非独立非执行董事身份留任董事会。
Sources (3)出处（3）
1. EG KAH YEE 89,271,427 12.001 2,000,002(a) 0.268
The position of Chairman is currently headed by the Managing Director, Eg Kah Yee.
Apart from his brother, Eg Kaa Chee, who is also a Non-Independent Non-Executive Director of the Company, he does not have any family relationship with any of the Directors and/or major shareholders of the Company.
The group carries out recurrent related party transactions with United Crest Healthcare Pte Ltd, connected to See Lee Ming and Jonathan Chuan Jack Eg, amounting to RM13,848,751 in 2025 for IP licensing, software and hardware sales. This is the same amount as the revenue from the single customer above.集团与关联人士 See Lee Ming 及 Jonathan Chuan Jack Eg 有关连的 United Crest Healthcare Pte Ltd 进行经常性关联交易，2025 年金额为 RM13,848,751，涵盖知识产权许可、软件及硬件销售。这与上述单一客户带来的营业额是同一数额。
Sources (2)出处（2）
UCrest Group (provider of products and services) United Crest Healthcare Pte Ltd (recipient of products and services) IP Licensing, sales of Software License and Hardware including installation, troubleshooting and outsourcing.
Person Connected See Lee Ming Jonathan Chuan Jack Eg 13,848,751
Messrs UHY Malaysia resigned as auditors on 22 April 2025 and Morison LC PLT was appointed as auditor for the financial year ended 31 May 2025, while the nomination committee sought a replacement for director Ms Chuan Tsui Ju.Messrs UHY Malaysia 于 2025 年 4 月 22 日辞去审计师职务，Morison LC PLT 被委任接任截至 2025 年 5 月 31 日止财政年度的审计师，提名委员会亦在寻找董事 Ms Chuan Tsui Ju 的接替人选。
Sources (3)出处（3）
Subsequent thereto on 22 April 2025, the Company had received a notice in writing from Messrs UHY Malaysia on their resignation as Auditors of the Company.
The AC had subsequently reviewed and recommended that Morison LC PLT be appointed as the External Auditor of the Company for the financial year ended 31 May 2025 in place of Messrs UHY Malaysia
Accordingly, the NC would be sourcing for a new Independant Non-Executive Director to be appointed to replace Ms Chuan Tsui Ju on the Board and Board Committees will be made at a Later Stage, subject to further deliberation by the NC and the Board.
Revenue by country, 20252025 年各国家/地区营业额占比
Sources (2)出处（2）
Malaysia 57,567 130,555 1,282,386 2,540,206
Singapore 18,060,194 15,295,951 - -
Major events大事记
Sources (1)出处（1）
(a) On 20 July 2022, the Company had signed a Service Level Agreement (“SLA”) with Malaysian Genomic Resources Centre Berhad (“MGRC”) to integrate genome services into digital health platform, iMedic, elevating the healthcare services to the next level.
Sources (1)出处（1）
(b) On 19 December 2022, the Company announced that its wholly-owned subsidiary, Palette System Sdn. Bhd. had entered into a Healthcare Cloud Deal with value of over RM1.25 million that empower “home is clinic” development with K Company.
Sources (3)出处（3）
(a) On 14 March 2024, the Company entered a Business Partnership Agreement (“BPA”) with Mediprima Healthcare (M) Sdn. Bhd. to digitalise the clinics with digital health, integrate Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) into the medical services.
(b) On 21 March 2024, the Company entered a BPA with StayOnline Ltd (“StayOnline”) to digitalise the health industry with Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) into StayOnline digital payment platform offering intelligent medical services to the population in Rwanda, Kenya, Uganda, and Zambia.
(c) On 3 April 2024, the Company entered a BPA with MDC Asia Link Berhad (“MDC”) to digitalise with integrate Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) with iMedic™ Platform.
Sources (2)出处（2）
(a) On 18 June 2024, the Company has launched iMedic Optics™, the eye health screening and diagnosis platform using Artificial Intelligence (“AI”) technology to process retinal images from the fundus camera.
(b) On 3 July 2024, the Company had entered into a Distribution Agreement with Seecure Holding Corporation (“Seecure”) to engage Seecure to market and support the iMedic™ platform services including iMedic Optics™, the ophthalmology Artificial Intelligence product in the territory of North, Central and South America continents.
Sources (1)出处（1）
On 14 October 2024, the Company entered a Partnership Agreement (“Agreement”) with Singapore Paincare Holdings Limited (“Singapore Paincare”) to implement Artificial Intelligence (“AI”) powered digital transformation and blitz scale all its clinics in operational and medical processes to improve efficiency and patient efficacy.
Revenue and profit/loss营业额与盈利/亏损
Cash balances and total equity现金结余与总权益
20232023 年
The company increased its share capital from 621,877,450 units to 691,877,450 units through ESOS options exercised at RM0.0628 each, and 42,700,000 new shares were issued under a private placement. A reversal of impairment losses on trade receivables of RM3,391,109 was recognized.公司在按每股 RM0.0628 行使 ESOS 选项后，股份由 621,877,450 股增至 691,877,450 股；另通过私下配售发行了 42,700,000 股新股。此外，确认了 RM3,391,109 的应收账款减值损失减记倒回。
Sources (3)出处（3）
During the financial year, the Company increased its issued and paid up share capital from 621,877,450 units to 691,877,450 by way of issuance of new ordinary shares pursuant to the exercise of options under Employee Share Option Scheme (“ESOS”) at an exercise price of RM0.0628 each.
As at the date of this report, 42,700,000 new Ordinary Shares were issued under the Private Placement pursuant to the above general mandate, which were subsequently listed and quoted on the ACE Market of Bursa Malaysia Securities Berhad.
Impairment losses reversed (3,391,109) - - -
20242024 年
Share capital increased from 691,877,450 units to 741,877,450 units via a private placement of 50,000,000 shares at RM0.0935 per share for working capital. The group recorded a reversal of impairment losses on trade receivables of RM7,065,039 and recommended no dividend.公司以每股 RM0.0935 私下配售 50,000,000 股筹集营运资金，股份由 691,877,450 股增至 741,877,450 股。集团记录了 RM7,065,039 的应收账款减值损失倒回，且未建议派发股息。
Sources (4)出处（4）
During the financial year, the Company increased its issued and paid up share capital from 691,877,450 units to 741,877,450 units by way of issuance of new ordinary shares pursuant to the private placement at an issue price of RM0.0935 each for working capital purposes.
As at the date of this report, 50,000,000 new ordinary shares were issued under the Private Placement pursuant to the above general mandate.
Impairment losses reversed (7,065,039) (3,391,109) - -
The Directors do not recommend any dividend in respect of the current financial year.
20252025 年
Issued share capital increased from 741,877,450 units to 743,827,450 units following the exercise of ESOS options at RM0.0988 per share. Reversal of impairment losses on trade receivables was RM6,836,769, and no dividend was declared.在按每股 RM0.0988 行使 ESOS 选项后，已发行股本由 741,877,450 股增至 743,827,450 股。应收账款减值损失倒回为 RM6,836,769，且未宣派股息。
Sources (3)出处（3）
During the financial year, the Company increased its issued and paid-up share capital from 741,877,450 units to 743,827,450 units by way of issuance of new ordinary shares pursuant to the exercise of options under Employees Share Option Scheme (“ESOS”) at an exercise price of RM0.0988 each.
Reversal of impairment losses recognised on trade receivables (6,836,769) (7,146,922) (22,651) -
No dividend has been paid or declared by the Company since the end of the previous financial year.
Across the three years三年合看
Trade receivables concentration remained high, with one major customer owing RM31,461,675 in 2025 (99% of trade receivables) and RM30,935,135 in 2024 (98%), while two customers owed RM21,924,584 in 2023 (98%). Deferred payment terms allow eligible customers to pay over up to 36 months, reaching RM32,251,084 in 2025.应收账款集中度持续居高，单一主要客户在 2025 年欠款 RM31,461,675（占应收账款 99%），2024 年欠款 RM30,935,135（占 98%），而 2023 年两家客户欠款 RM21,924,584（占 98%）。延迟付款条款允许符合条件的客户在长达 36 个月内付款，2025 年相关金额达 RM32,251,084。
Sources (3)出处（3）
The Group’s major concentration of credit risk relates to the amount owing by a major customer (2024: a major customer) amounted to RM31,461,675 (2024: RM30,935,135) which constituted approximately 99% (2024: 98%) of its trade receivables as at the end of the reporting period.
The Group’s major concentration of credit risk relates to the amounts owing by two customers (2022: two customers) amounted to RM21,924,584 (2022: RM11,224,209 which constituted approximately 98% (2022: 99%) of its trade receivables as at the end of the reporting period.
Gross trade receivables include receivables on deferred payment terms amounting to RM32,251,084 (2024: RM25,527,521 and 2023:RM13,192,615), which allow an eligible customer to pay for the service rendered over a period of up to 36 months.
Still to be spent尚未支出的承诺
Unused private placement proceeds allocated for working capital stood at RM1.643 million at 31 May 2025, down from RM12.85 million in 2023. There were 18,050,000 outstanding unexercised ESOS options at 31 May 2025.截至 2025 年 5 月 31 日，未动用的私下配售营运资金结余为 RM1.643 million，低于 2023 年的 RM12.85 million。截至 2025 年 5 月 31 日，尚有 18,050,000 份未行使的 ESOS 选项。
Sources (3)出处（3）
Working Capital 6,213 4,570 1,643
Working Capital 20,748 7,898 12,850
Outstanding options unexercised as at 31 May 2025 4,000,000 300,000 13,750,000 18,050,000
Four years of figures四年数字
Group figures, in RM, as printed in the statements.集团数字，单位令吉，照财务报表所印。
| Group集团 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| RM令吉 | RM令吉 | RM令吉 | RM令吉 | |
| Revenue营业额 | 12,346,797 | 13,557,373 | 16,452,202 | 18,117,761 |
| Profit/(Loss) before taxation税前盈利/（亏损） | (35,129,072) | 100,901 | 4,591,491 | 4,767,614 |
| Profit/(Loss) for the financial year年度盈利/（亏损） | (6,895,173) | 100,901 | 4,591,491 | 4,730,206 |
| Cash and bank balances现金与银行结余 | 11,438,610 | 5,474,977 | 5,806,335 | 8,907,761 |
| Fixed deposits with licensed banks持牌银行定期存款 | 4,048,339 | 12,157,719 | 13,330,875 | 8,630,174 |
| Total equity总权益 | 25,400,584 | 32,464,974 | 42,440,700 | 44,308,017 |
On a computer, hover over a figure for the report and page it is printed on.在电脑上把鼠标移到数字上，可看到它印在哪份年报的哪一页。
Said and done说过的与做到的
| What the reports said年报说要做的 | What later reports show之后年报显示的 | Status状态 |
|---|---|---|
| iMedic platform expected to be fully compliant with HealthierSG requirements by end of November 2023.iMedic 平台预计于 2023 年 11 月底前完全符合 HealthierSG 要求。 | iMedic passed tests and was certified as a HealthierSG Smart Clinic Management System platform in Singapore.iMedic 通过测试，并在新加坡获认证为 HealthierSG 智慧诊所管理系统平台。Sources (3)出处（3）The platform is expected to be fully compliant with the requirements of HealthierSG by end of November 2023. iMedic™ has passed all the test to be qualified as one of the HealthierSG Smart Clinic Management System (“SmartCMS”) platforms. iMedic™ has been certified as one of the HealthierSG Smart Clinic Management System (“SmartCMS”) platforms in Singapore. | Completed已完成 |
| Group expected 3D or MD printing to become a significant revenue contributor.集团预计 3D 或 MD 打印将成为主要营业额贡献来源。 | iMedic remained the primary revenue driver in 2024 and 2025, with balance from customization and maintenance services.iMedic 在 2024 和 2025 年仍为主要营业额驱动力，其余来自定制与维护服务。Sources (3)出处（3）The Group expects to see 3D or MD printing would be a significant revenue contributor. The flagship product, iMedic™ contributed almost all the revenue and the remaining is attributed by customisation and maintenance services of the platform. The flagship product, iMedic™, remained the primary revenue driver, contributing the bulk of income, while the balance came from customization and maintenance services related to the platform. | Not a major contributor未成为主要贡献来源 |
| Contract entered with MDC Asia Link Berhad on 3 April 2024 to digitalize with iMedic platform.于 2024 年 4 月 3 日与 MDC Asia Link Berhad 签约，以 iMedic 平台推行数字化。 | Deployed iMedic digital clinics in GP and dental clinic chains in the domestic market.在本地市场的全科与牙科连锁诊所部署了 iMedic 数字诊所。Sources (3)出处（3）(c) On 3 April 2024, the Company entered a BPA with MDC Asia Link Berhad (“MDC”) to digitalise with integrate Artificial Intelligence (“AI”) and Internet of Medical Things (“IoMT”) with iMedic™ Platform. This contract has been commenced and effect has been reflected in the financial statements during the financial year. iMedic™ digital clinics have already been deployed in GP and dental chains, and adoption continues to grow. | Carried out已执行 |
| Distribution agreement signed with Seecure Holding Corporation expected to generate revenue from North, Central and South America.与 Seecure Holding Corporation 签署的分销协议预计从北美、中美与南美市场带来营业额。 | The segment note shows no revenue from the United States in 2025 (RM25,754 in 2024).分部附注显示 2025 年没有来自美国的营业额（2024 年为 RM25,754）。Sources (3)出处（3）It has inked a distribution agreement with one of the leading telemedicine software companies, Seecure Inc. for the North America, Central and South America markets. The agreement is expected to contribute significant revenue to the Group. United States - 25,754 - - 18,117,761 15,931,302 1,282,386 2,540,206 | No US revenue in 20252025 年无美国营业额 |
| iMedic Optics launch expected to become one of the key revenue contributors.推出的 iMedic Optics 预计将成为主要营业额贡献来源之一。 | Reported adoption across GP clinics and optical shops, with expectation to become a core revenue driver in coming years.报告显示已在全科诊所与眼镜店获得采用，并预计在未来几年成为核心营业额驱动力。Sources (3)出处（3）iMedic™ Optics has started to generate revenue and it is expected to be one of the key contributors to the revenue of the Group. We anticipate it becoming one of our core revenue drivers in the coming years. Uptake of iMedic™ Optics has been highly encouraging, with adoption across GP clinics, optical shops, and endocrinology practices. | Still in progress仍在推进中 |
What the reports leave open年报留下待看的事
- Collection of RM31,461,675 in trade receivables owed by a single customer representing 99% of total trade receivables under an agreed repayment schedule.单一客户欠付的 RM31,461,675 应收账款（占总应收账款 99%）在协定还款计划下的回收情况。
Sources (2)出处（2）
As at 31 May 2025, the Group recorded revenue and trade receivable of RM13,848,751 and RM31,461,675 respectively, representing 76% and 99% of the Group’s total revenue and total trade receivables respectively, which was derived from a customer.
Obtained agreed repayment schedule between the Group and the customer, and verified collection of this customer during and after year end to assess recoverability of the outstanding balances and occurrence of revenue;
- Selection and appointment of a new independent non-executive director to replace Ms Chuan Tsui Ju on the board and board committees.遴选并委任新独立非执行董事以接替 Ms Chuan Tsui Ju 在董事会及董事会委员会职务的进展。
Sources (1)出处（1）
Accordingly, the NC would be sourcing for a new Independant Non-Executive Director to be appointed to replace Ms Chuan Tsui Ju on the Board and Board Committees will be made at a Later Stage, subject to further deliberation by the NC and the Board.
- Execution of international expansion strategies in the United States, Europe and China; the segment note shows no revenue from the United States in 2025.在美国、欧洲和中国拓展业务策略的执行情况；分部附注显示 2025 年没有来自美国的营业额。
Sources (2)出处（2）
Looking ahead, the Group anticipates revenue growth to be driven by markets in the US, ASEAN, Europe, and China.
United States - 25,754 - - 18,117,761 15,931,302 1,282,386 2,540,206
Facts as printed in the company's annual reports, with the page of each; no rating and no advice. Built 2026-10-11.内容为公司年报所印的事实，并注明页码；不评级，不构成投资建议。生成日期 2026-10-11。